REG - Roquefort Theraptcs. - Conversion of CLNs

Roquefort TherapeuticsAnnouncement

09/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI7191Ka&default-theme=true

RNS Number : 7191K  Roquefort Therapeutics PLC  09 December 2025

9 December 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Conversion of CLNs

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces that the Company has received notices, in two tranches, to convert a
total face value of £80,000 convertible loan notes (the "CLNs") resulting in
the issue of 6,282,264 new ordinary shares in the Company (the "CLN Shares").

 

In accordance with the terms of the CLNs, which were issued and announced on
23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is
included in the conversion into the Company's ordinary shares of £0.01 each
("Ordinary Shares"). The conversion price of the first tranche of the CLNs
representing a face value of £30,000 is 1.81p and the conversion price of the
second tranche of the CLNs representing a face value of £50,000 is 1.29p. The
conversion price is calculated as being 90% of the price equal to the 10-day
volume-weighted average price calculated backwards from the date, which is
three business days prior to the notice of conversion given to the Company.
Following conversion of these CLNs, the Company has CLNs with a face value of
£257,894 outstanding.

 

Admission and Total Voting Rights

Application will be made for the CLN Shares to be admitted to trading on the
London Stock Exchange's Main Market for listed securities, which is expected
to occur on or around 16 December 2025 ("Admission"). The CLN Shares will
rank pari passu in all respects with the Company's existing Ordinary Shares.

 

Following Admission, the Company's issued share capital will comprise
163,726,294 Ordinary Shares in issue, with each share carrying the right to
one vote. The Company does not hold any Ordinary Shares in treasury. The
figure of 163,726,294 Ordinary Shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or of a change to their interest in the
Company under the FCA's Disclosure and Transparency Rules.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)   +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Broker to the Company)       +44 (0)20 4530 6926

 Damon Heath
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper

 

LEI: ‎254900P4SISIWOR9RH34

 

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed
transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which
will result in the Company acquiring the exclusive licence rights to AO-252, a
novel first-in-class, first-in-human new drug alternative targeting the TACC3
protein for the treatment of certain cancers, initially announced by the
Company on 8 September 2025.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CONUPGAPPUPAGMR



            Copyright 2019 Regulatory News Service, all rights reserved